** Surgical device maker AxoGen's shares AXGN.O rise 2.6% to $18.5 premarket
** Co reports Q4 profit of 7 cents/share, beating analyst estimates of 3 cents/share, as per data compiled by LSEG
** Co posts Q4 revenue of $49.4 mln vs analyst est of $48.6 mln
** AXGN forecasts 2025 revenue growth of 15% to 17%
** Stock has risen 72% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。